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ABSTRACT
Oral levothyroxine (LT4) is the standard ther-
apy for patients with hypothyroidism. Oral LT4
is available in several formulations, including
tablets, soft gel capsules and oral solution.
Multiple brand-name and generic LT4 tablets
are available. In the US, the Food and Drug
Administration (FDA) has developed a protocol
for establishing bioequivalence of LT4 formu-
lations based on serum thyroxine (T4) levels
after a single oral dose administered to healthy
volunteers. This protocol has been criticized by
professional endocrinology associations for
using healthy individuals and ignoring serum
thyroid-stimulating hormone (TSH) levels. In
addition, the protocol did not initially correct
for baseline T4 levels, although this was chan-
ged in a later version. There are concerns that
the FDA’s protocol could allow products with
clinically significant differences in bioavailabil-
ity to be declared therapeutically equivalent
and interchangeable. Once a generic LT4 has
been shown to be bioequivalent to a brand-
name LT4, it may be substituted for that brand-
name LT4 with no need for dose adjustment or
follow-up therapeutic monitoring. Often, the
substitution is made by the pharmacy without
the physician’s knowledge. Even small differ-
ences between LT4 formulations can cause sig-
nificant changes in TSH levels. This may be a
particular concern in vulnerable populations,
including elderly, pregnant, and pediatric
patients. Problems that can be encountered
when switching between formulations or when
original products are reformulated are discussed
in this review. These problems include altered
efficacy and adverse events, some of which can
be caused by excipients. Patients should be
maintained on the same LT4 preparation if
possible. If the LT4 preparation is changed, TSH
levels should be evaluated and, if necessary, the
dose of LT4 adjusted.
Funding: Merck.
Enhanced Digital Features To view enhanced digital
features for this article go to https://doi.org/10.6084/
m9.figshare.9707564.
S. Benvenga (&)
Endocrinology Section, Department of Clinical and
Experimental Medicine, University of Messina,
Messina, Italy
e-mail: s.benvenga@live.it; sbenvenga@unime.it
S. Benvenga
Master Program on Childhood, Adolescent and
Women’s Endocrine Health, University of Messina,
Messina, Italy
S. Benvenga
Interdepartmental Program of Molecular and
Clinical Endocrinology and Women’s Endocrine
Health, University Hospital, AOU Policlinico G.
Martino, Messina, Italy
A. Carlé
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PLAIN LANGUAGE SUMMARY
Orally administered levothyroxine (LT4) is the
standard treatment for hypothyroid patients.
Several different LT4 products are available.
Sometimes, pharmacists may substitute a
patient’s usual LT4 product for a less expensive
one, especially if this is the policy of the
organisation that is paying for the medicine
(e.g., health insurer or public health provider).
Because even small differences between LT4
products can have significant effects on how
well the drug works, or the types of side effects
it may cause, most clinical practice guidelines
recommend that patients stay on the same LT4
preparation if possible. If the patient needs to
switch to a new LT4 product, physicians should
ensure that the dose is adjusted to suit the
patient.
INTRODUCTION
Thyroid hormone replacement therapy with
oral levothyroxine (LT4) is the standard treat-
ment for patients with hypothyroidism [1–3].
The goals of treatment include resolution of
symptoms and signs of hypothyroidism and
normalization of circulating thyroid-stimulat-
ing hormone (TSH) levels [3]. Orally adminis-
tered LT4 is available in several formulations
(including tablet, soft gel capsule and liquid
formulations) [2, 4], and LT4 tablets are avail-
able in multiple branded and generic forms [2].
The traditional tablet formulation contains LT4
sodium, a stable salt, and a variety of inactive
excipients, the composition of which may affect
tablet stability and pharmacokinetics [4–8].
The US Food and Drug Administration (FDA)
defines a ‘generic drug’ as a medication that has
the same dosage form, safety, strength, route of
administration, quality, performance charac-
teristics and intended use as an already mar-
keted brand-name medication [9]. The
European Medicines Agency (EMA) defines
generic drugs as those that have the same
qualitative and quantitative composition of
active substances and the same pharmaceutical
form as the reference drug and whose bioe-
quivalence with the reference drug has been
demonstrated by appropriate bioavailability
studies [10]. With regard to generic and branded
LT4 preparations, endocrinologists around the
world differ in their preferences. According to a
survey of 880 members of The Endocrine Soci-
ety (TES), the American Thyroid Association
(ATA) and the American Association of Clinical
Endocrinologists (AACE), 49.9% of respondents
preferred brand-name LT4, while 49.3% pre-
ferred generic LT4. However, among European
members, who represented 9.2% of respon-
dents, the proportion of those who preferred a
brand-name drug was 58.8% [11].
At present, the FDA uses serum thyroxine
(T4) levels to establish the bioequivalence of
LT4 products [12]. Based on the FDA criteria for
bioequivalence (described in detail in the sec-
tion ‘‘Bioequivalence and interchangeability’’),
substitution between bioequivalent generic and
brand-name LT4 can be automatically per-
formed with no need for dose adjustment.
There is ongoing debate around concerns that
the currently used pharmacokinetic approach
for assessing the bioequivalence of LT4 products
could allow products with clinically significant
differences in bioavailability to be declared
therapeutically equivalent and interchangeable
[3, 12–19]. Therefore, the ATA, the ES and the
AACE have issued a joint statement encourag-
ing consistent use of the same branded or gen-
eric LT4 formulation in individual patients (i.e.,
patients should not be regularly switched from
one brand to another, from a branded to a
generic product or from a generic product to
another generic product) [13]. These recom-
mendations have since been reinforced by
guidelines from the Endocrine Society of Aus-
tralia, the European Thyroid Association and
Thyroid Federation International [3, 20, 21],
and are summarized in Table 1. If a switch to
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another LT4 formulation is made (for instance,
because the waiting time between LT4 ingestion
and breakfast is an issue for the patient or
because the patient is co-ingesting drugs known
to impair the intestinal absorption of LT4),
repeat thyroid function testing is recommended
(i.e., serum TSH testing within 4 weeks to
determine whether dose adjustment is required)
[3, 13, 19, 21].
Switching was considered to be a particular
concern in vulnerable populations, including
elderly, pregnant and pediatric patients [3, 13],
especially since these patients are often exclu-
ded from the studies undertaken to establish
bioequivalence [10]. This review describes
problems that can be encountered when
switching between formulations or when origi-
nal products are reformulated.
METHODS
In December 2018, the PubMed database was
searched for articles of potential interest using
‘‘levothyroxine’’ in combination with each of
the following search terms: ‘‘interchangeabil-
ity’’, ‘‘bioequivalence’’, ‘‘formulations’’ and
‘‘generic’’. These combinations returned 10,
120, 128 and 79 entries, respectively. The titles
and abstracts of English-language articles iden-
tified through the search were then reviewed to
determine relevance. Furthermore, the refer-
ence lists of the relevant articles were used to
identify additional literature. This article is
based on previously conducted studies and does
not contain any studies with animals performed
by any of the authors. Some of studies cited
include analyses, or studies with human
Table 1 Summary of practices for physicians and patients, with regard to switching levothyroxine formulations, that were
proposed in international/national guidelines/statements [3, 13, 20, 21]
For physicians
Patients should be maintained on the same brand name of levothyroxine product
If the brand of levothyroxine medication is changed from one brand to another brand, from a brand to a generic
product or from a generic product to another generic product:
Patients should be re-evaluated and retested by measuring serum TSH in 6 weeks;
The drug should be retitrated as needed
For patients
Use the same brand of thyroid medication throughout your treatment
Thyroid disease often requires lifelong therapy and is best managed with consistent and precise treatment with the
same brand of thyroid hormone
Your doctor may change your dose of thyroid hormone, but the brand of your thyroid hormone medication should
always stay the same
When you go to the pharmacy, do not change the brand of your thyroid medication without checking with your doctor
You should not change your dose from one brand of thyroid medication to another, from your brand of thyroid
medication to a generic product, or from one generic product to another without first checking with your doctor
If your doctor changes the type of thyroid medication you are taking, you will need to have repeat blood tests and visits
to your doctor to make sure that you are on the correct dose. Your dose may need to be readjusted if your thyroid
medication is changed
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participants, performed by the authors and
completed prior to the initiation of this
manuscript.
BIOEQUIVALENCE
AND INTERCHANGEABILITY
Bioequivalence of LT4 formulations is defined
as the absence of a significant difference in
bioavailability, expressed in terms of the maxi-
mum concentration (Cmax) or area under the
curve (AUC), of the active ingredient of a drug
product when administered at the same molar
dose in healthy volunteers [14, 18, 22]. A
specific LT4 pharmacokinetic protocol for
bioequivalence has been developed by the FDA
[2, 23]. In this protocol, a single oral dose of
600 lg of LT4 is administered to healthy vol-
unteers [12]. The 90% confidence interval (CI)
for test/reference product geometric mean AUC
and Cmax ratios of serum T4 must be in the
80–125% range [14]. Note that the 90% CI for
narrow therapeutic index drugs is 90–111.1%,
and LT4 is often considered a narrow thera-
peutic index drug [13, 14, 24]. The FDA assigns
an AB ? number TE code to LT4 tablets
(Table 2) [25–33]. Products with the same TE
code are considered therapeutically equivalent
[32].
The LT4 bioequivalence protocol produced
by the FDA has been criticized by professional
endocrinology associations. In their joint letter,
the ATA, the ES and the AACE pointed out that
pharmacokinetic assessments are not suit-
able for biologics and that the protocol does not
include TSH assessment [13]. Omitting TSH is
illogical, considering that it is the most sensitive
and easily measurable biochemical target of
thyroid hormone action and because of its
importance for monitoring the adequacy of LT4
treatment [14, 24]. Yet, we think that with a
half-life of approximately 1 h, a minimum of
four measurements (two baseline, one inter-
mediate and one final) could be added to the
FDA protocol with little extra cost incurred. In
addition, the FDA protocol did not initially
include correction for baseline T4 levels [12].
According to the 2014 ATA guidelines, a more
appropriate measure of bioequivalence would
be based on T4, triiodothyronine (T3) and TSH
levels after daily administration for at least
4–6 weeks conducted in athyreotic individuals
[3]. These guidelines refer to research conducted
by Mayor and colleagues [34], who re-analyzed
data previously published by Dong and col-
leagues [35], showing that LT4 products con-
sidered to be both pharmacokinetically and
therapeutically bioequivalent were not in fact
therapeutically bioequivalent when correction
for baseline T4 was applied [34]. The FDA later
included correction for baseline T4 in its pro-
tocol [12]. Another drawback of FDA’s protocol
is the use of healthy volunteers. In a study that
included 4 patients with goiter, 12 euthyroid
controls and 10 primary hypothyroid controls
who were administered LT4 1000-lg tablets,
serum T4 curves in the two control groups were
shown to be not entirely superimposable [36].
There are no equivalent European guidelines
for the demonstration of LT4 formulation
bioequivalence, but the FDA bioequivalence
guidelines for LT4 are referred to in European
countries [37, 38]. Instead, the relevant Euro-
pean guideline is the 2010 European Medicines
Agency Guideline on the Investigation of Bioe-
quivalence [10]. This guideline is focused on
immediate-release formulations of chemical
entities with systemic action, while modified-
release, transdermal and orally inhaled formu-
lations, as well as biologicals, are not covered.
According to this Guideline, medicinal products
containing the same active substance are con-
sidered to be bioequivalent ‘‘if they are phar-
maceutically equivalent or pharmaceutical
alternatives and their bioavailabilities (rate and
extent) after administration in the same molar
dose lie within acceptable predefined limits.
These limits are set to ensure comparable
in vivo performance, i.e., similarity in terms of
safety and efficacy’’ [10]. Medicinal products are
considered to be pharmaceutically equivalent if
they ‘‘contain the same amount of the same
active substance(s) in the same dosage forms
that meet the same or comparable standards’’
[10]. Of note, pharmaceutical equivalence does
not always imply bioequivalence because dif-
ferences in excipients and the manufacturing
process can affect pharmacokinetics [10].
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According to this Guideline, bioequivalence
studies should be conducted in healthy volun-
teers unless the drug is associated with safety
concerns that would make this unethical. In
most cases, it should be possible to extrapolate
the results of such studies to other populations
such as the elderly, children and patients with
renal or liver impairment [10].
In order to assess bioequivalence after a sin-
gle dose, the Guideline recommends analyzing
AUC(0–t) or, when relevant, AUC(0–72h), and
Cmax. In order to assess bioequivalence of
immediate release formulations at a steady
state, analysis of AUC(0–s) and Cmax,SS is recom-
mended. Bioequivalence is established when
the 90% CI for the ratio of the test and reference
products is C 80.00% and B 125.00% when
rounded to two decimal places. The acceptance
interval may need to be narrowed to
90.00–111.11% for products with narrow ther-
apeutic range [10].
In Europe, medicinal products are consid-
ered to be therapeutically equivalent if they
contain the same active substance or therapeu-
tic moiety and have the same clinical efficacy
and safety. Therapeutic equivalence can be
established by demonstrating bioequivalence if
the excipients contained within the products
are generally recognized as not affecting their
safety and efficacy. Bioequivalence can be
established using pharmacokinetic instead of
therapeutic data if, in the same individual,
similar plasma concentrations over a similar
Table 2 FDA therapeutic equivalence ratings for currently available levothyroxine tablet products [25–33]
Levothyroxine
tablet product
Reference
listed druga
Therapeutic
equivalence
codeb
Inactive ingredientsc
Brand name
Unithroid Yes AB1, AB2, AB3 Acacia, colloidal silicon dioxide, corn starch, lactose, magnesium
stearate, microcrystalline cellulose, sodium starch glycolate
Synthroid Yes AB1, AB2 Acacia, confectioner’s sugar (contains corn starch), lactose
monohydrate, magnesium stearate, povidone, talc
Levoxyl Yes AB1, AB3 Calcium sulfate dehydrate, croscarmellose sodium, magnesium
stearate, microcrystalline cellulose, sodium bicarbonate
Levo-T No AB1, AB2, AB3 Magnesium stearate, microcrystalline cellulose, colloidal silicone
dioxide, sodium starch glycolate
Euthyrox No AB2 Citric acid anhydrous, corn starch, gelatin, magnesium stearate,
mannitol, sodium croscarmellose
Generic
Levothyroxine
sodium
(Mylan)
No AB1, AB2, AB3,
AB4
Butylated hydroxyanisole, colloidal silicon dioxide, crospovidone,
ethyl alcohol, magnesium stearate, mannitol, microcrystalline
cellulose, povidone, sodium lauryl sulfate, sucrose
a A drug identified by the FDA as a product on which an applicant relies in seeking approval of an abbreviated new drug
application for a generic product
b If bioequivalence to a reference listed drug product is demonstrated, the product will be given the same code as the
reference listed drug it was compared against: AB1 vs. Unithroid, AB2 vs. Synthroid, AB3 vs. Levoxyl; AB4 vs. Levothroid/
Thyro-Tabs (now discontinued). One common code indicates therapeutic equivalence between products
c All formulations except Euthyrox also contain colorants that differ according to tablet dose
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time course will result in similar concentrations
at the site of action [39].
Tablet Formulations
In the US, physicians currently have a choice of
several LT4 sodium tablet preparations, five
branded products and one generic formulation
(Table 2) [31]. According to the US FDA system
of evaluation for therapeutic equivalence,
preparations with the same TE code are con-
sidered to be interchangeable (Table 2) [31, 32].
Although several LT4 products do have similar
pharmacokinetic performance, this is not
assured for each of the AB-rated pairs because
not all have been directly compared in phar-
macokinetic studies [2]. A range of LT4 tablet
brand-name and generic formulations are also
available in Europe and used interchangeably
(brand-name products include Eltroxin, Euthy-
rox/Levothyrox, Thyrax, Tirosint, Eutirox,
Letrox and Levaxin) [21, 38, 40, 41].
According to an analysis of US medical
insurance claims data between 2007 and 2016,
73.6% of thyroid hormone prescription fills
were for generic LT4 and 23.4% were for brand-
name LT4 (the remainder comprised other
thyroid hormone drugs) [42]. The proportion of
generic LT4 fills increased from 59.8% in 2007
to 84.9% in 2016. Prescription of brand-name
LT4 was more common for women and by
endocrinologists, while it was less common for
elderly patients [42].
Interestingly, generic LT4 preparations are
no longer used in France, partly because doctors
are reluctant to prescribe them [43]. Based on
the authors’ experience, generic LT4 tablets are
rarely used in Italy or Denmark. In addition,
Danish pharmacies produce small amounts of
lactose-free LT4 tablets with microcrystalline
cellulose and potato starch as the only excipi-
ents present.
Soft Gel and Liquid Formulations
Soft gel and liquid LT4 formulations are alter-
native dosage forms of LT4 [2, 22, 37]. Lower
doses of LT4 are generally required with these
formulations compared with traditional tablets,
because dissolution of tablet excipients does not
need to occur before LT4 is available for bowel
absorption [2, 44]. Soft gel and liquid formula-
tions are preferable in patients who have
reduced intestinal absorption of LT4 due to
gastrointestinal disorders or concomitant drugs
[41]. Any change between various LT4 formu-
lations in such patients should be performed
with special care.
Tirosint/Tiche/Syntroxine is a unique LT4
product available in the USA and Europe as a
soft-gel capsule, and in Europe as a liquid for-
mulation [2, 31, 37]. Lactose-free soft gel (LT4
dissolved in glycerin surrounded by a layer of
gelatin) and liquid formulations (LT4 dissolved
in glycerol and ethanol) are bioequivalent to
traditional LT4 tablets in healthy volunteers,
but may perform better in patients with gas-
trointestinal malabsorption conditions and
when taken with foods and certain interacting
drugs, and in patients with TSH values close to
the limits of the desired therapeutic range
[6, 37, 41, 44–53]. However, most studies
showing better absorption with soft gel or liquid
LT4 formulations compared with tablets were
published after the ATA guidelines were
released. As a result, there are no specific rec-
ommendations for the use of such formulations
in these circumstances, but it has been sug-
gested that they may be useful in patients with
allergies or side effects to the excipients found
in some LT4 tablets (e.g., lactose in Synthroid)
[3, 54–56].
Caution is advised when prescribing ethanol-
containing products to certain patients,
including pregnant and lactating women and
patients with liver disease or epilepsy [41].
However, no adverse events were reported in a
study that included 14 pregnant women treated
with liquid LT4 [57]. A new oral solution free
from ethanol, propylene glycol and preserva-
tives that has been shown to be bioequivalent to
Tirosint capsules has also been developed [58].
An ethanol-free liquid formulation of Eltroxin is
also available in Europe, as are several generic
versions [41]. However, this formulation con-
tains sodium methyl parahydroxybenzoate as a
preservative, which may cause allergic reac-
tions, including delayed reactions [59].
S64 Adv Ther (2019) 36:S59–S71
REFORMULATION
To minimize the variability of LT4 products, the
FDA now requires LT4 products to retain
95–105% of labeled LT4 content over the
expected shelf life of the product instead of the
previously accepted range of 90–110% [60]. The
US Pharmacopeia revised their monograph for
levothyroxine sodium tablets to support this
change. These revisions went into effect in
October 2009 [61]. The French Agence Natio-
nale de Sécurité des Médicaments (ANSM) also
requires that LT4 products retain 95–105% of
LT4 content, whereas 90–105% is acceptable in
the UK [24, 38].
Several branded products have been refor-
mulated to meet the new standards, including
Euthyrox/Levothyrox and Levoxyl tablets and
Tirosint soft-gel capsules [2, 62–64]. Using the
FDA criteria, the new formulations have been
shown to be bioequivalent to the old formula-
tions (Table 3) [62–64]. Geometric mean
AUC(0–72h) and Cmax ratio 90% CIs for Euthyrox
were both within the 90–111% acceptance
range for narrow therapeutic index drugs
[62, 63]. The Euthyrox tablet formulation
available since March 2017 no longer contains a
lactose excipient, which may be beneficial for
patients who are lactose-intolerant [24, 43].
TSH LEVELS AFTER GENERIC
SUBSTITUTION
The TSH reference range for the general popu-
lation is 0.4–4.5 mIU/L [1, 3], but may increase
with age (depending on dietary iodine intake),
so that the upper limit is * 5–6 mIU/L in
patients aged[70–90 years [65]. For example,
in Denmark, where the populations in most
regions are at least mildly iodine-deficient, TSH
levels do not increase with age and may actually
decrease in areas with moderate iodine defi-
ciency [66, 67]. Considering the limitations in
methodology for establishing bioequivalence
for LT4 products, some variation in response
(biochemical and possibly symptomatic) can be
expected if patients are freely substituted from
refill to refill [2, 68].
Between 2005 and 2007, a pharmacovigi-
lance study was conducted by the major Amer-
ican endocrine societies to evaluate their
members’ experience with LT4 substitution
[68]. At the time, four brand-name and four
generic LT4 tablet preparations were available
in the US. A total of 199 adverse events associ-
ated with changes in TSH values were reported.
Of these, 177 (88.9%) were reported after LT4
tablets had been switched [68]. The switch was
made by the pharmacy in 99.4% of cases, and
91.6% of these were carried out without the
physician’s knowledge. There was a switch from
a brand-name LT4 preparation to a generic
preparation in 156 (88.1%) cases, from one
brand to another in 12 (6.8%) and from one
generic to another in 9 (5.1%) [68]. In 11.1% of
cases, adverse events were reported after refills
with the same LT4 preparation, while in most
cases, adverse events were reported after generic
substitution for brand-name LT4. Overall, TSH
values were within the expected reference range
in 78.9% of patients before the reported event,
whereas, at the time of the event, 47.7%
exceeded the expected reference range and
Table 3 Geometric mean ratios of pharmacokinetic parameters for baseline-adjusted total plasma thyroxine after admin-
istration of new versus old formulations of levothyroxine (600 lg) in healthy volunteers [70–72]
Parameter Euthyrox Levoxyl Tirosint
Cmax 101.7 (98.8–104.6) 92.5 (87.1–98.2) 103.1 (93.5–113.6)
AUC(0–48h) NA 96.9 (90.5–103.8) NA
AUC(0–72h) 99.3 (95.6–103.2) NA 109.8 (100.3–120.3)
AUC(0–48h) area under the concentration–time curve from 0 to 48 h, AUC(0–72h) area under the concentration–time curve
from 0 to 72 h, Cmax maximum concentration, NA not assessed
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35.2% had suppressed TSH values [68]. Symp-
toms suggestive of hyper- or hypothyroidism
were reported [68]. Some potentially serious
consequences of suboptimal LT4 therapy were
identified in vulnerable populations (e.g.,
elderly or very young patients), most of which
occurred after switching (96.3%) [68]. However,
several of the events described as serious by the
reporting clinicians may not have reached the
‘‘serious’’ threshold in clinical trials [68]. Of
note, in the US, only 9% of thyroid hormone
prescriptions were made by endocrinologists
according to the IMS National Prescription
Audit 2009. Although not specifically assessed
in this pharmacovigilance study, the cost of
additional clinical activity associated with
adverse clinical events after switching appear to
outweigh the lower prescription costs for gen-
eric drugs [69, 70]. Similar pharmacovigilance
data are lacking in European countries, such as
the UK [38].
A retrospective study of children with con-
genital hypothyroidism treated with either
Synthroid or generic LT4 noted no difference in
TSH levels or clinical outcomes, and the authors
suggested that this implied interchangeability
[71]. However, in an editorial published in the
Journal of Clinical Endocrinology and Metabolism,
Hennessey criticized this study for not directly
assessing interchangeability [19]. Moreover, the
generic preparation used could not be identified
in 44% of patients and only 11% used an
interchangeable generic preparation (the Mylan
LT4 product) [19].
A prospective, randomized, cross-over trial
conducted in pediatric patients with severe
congenital hypothyroidism showed that TSH
levels with Synthroid were significantly lower
than with another AB2-rated product (Levo-T
distributed as a generic and considered by the
FDA to be interchangeable with Synthroid) [72].
These results were unexpected because the
generic was reported to be 12.5% more
bioavailable than Synthroid. These results sug-
gest that these AB-rated products are not clini-
cally interchangeable in patients with severe
congenital hypothyroidism, and may have
implications for other vulnerable populations
[19, 72]. Hennessey, in the aforementioned
editorial, notes that these results highlight the
limitations of the FDA protocol for establishing
the bioequivalence of LT4 preparations, and
suggests that further consideration should be
given to the TSH-based protocol for establishing
the therapeutic equivalence that was proposed
by the AACE/ATA/TES [19, 73].
PROBLEMS ENCOUNTERED AFTER
FORCED SWITCHING
ON A NATIONAL LEVEL
Problems have been encountered in several
countries when patients have been forced to
switch LT4 products because of supply problems
or mandated transition to a reformulated pro-
duct that contained different excipients
[21, 43, 74].
Generic or Brand Substitution
In the Netherlands, there was a recent shortage of
the most commonly used LT4 brand (Thyrax),
resulting in a forced brand switch (mainly to LT4
Teva or Euthyrox) and an increase in the reported
number of adverse events [21]. Although Thyrax
and Euthyrox share some excipients in common
(corn starch, gelatin, lactose monohydrate), most
excipients are different. Thyrax Duotab 0.025-,
0.100- and 0.150-mg tablets contain talc, sodium
citrate dihydrate (E 331), gelatin, glycerol (E 422),
colloidal anhydrous silica (E 551), magnesium
stearate (E572), as well as colorants (E132 in the
0.025-mg tablet and E127 in the 0.150-mg tablet)
[75]. Teva levothyroxine tablets contain maize
starch, mannitol (E421), microcrystalline cellu-
lose, sodium citrate, acacia and magnesium stea-
rate [76]. Euthyrox tablets contain magnesium
stearate (E 572) and croscarmellose sodium (E 468)
[77]. Overall, 53% of patients using[100 lg/day
showed biochemical signs of over-supplementa-
tion [21]. In response, general advice was issued to
check serum TSH 6 weeks after any brand change,
and to consider dose reduction for patients
receiving[100 lg/day [21].
In February 2012, the UK Medicines and
Healthcare products Regulatory Agency sus-
pended the license for Teva levothyroxine
100-lg tablets following reports from
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prescribers and patients describing reduced
efficacy when switching from other levothy-
roxine products [78]. In October 2016, the sus-
pension was lifted after Teva reformulated the
tablets by making them lactose-free and
changing the manufacturing process [79].
Reformulation
In 2017, a switch was made to the new formu-
lation of Levothyrox (Euthyrox in other EU
countries) in France to comply with the
requirement for 95–105% potency specification,
and, by 2018, there had been[17,000 reports
of advers e events [21, 43]. As previously men-
tioned, the new formulation (lactose removed
and mannitol and citric acid added) had been
shown to be bioequivalent to the previous for-
mulation, and complied with the relatively
stringent bioequivalence criteria for narrow
therapeutic index drugs [21, 43, 63]. For adverse
events with reported TSH levels, approximately
60% occurred in patients with normal TSH
levels (suggesting that patients were receiving
the right dose), and 15–20% in patients with
TSH levels indicative of hypothyroidism or
hyperthyroidism [21]. These numbers are not
unusual by themselves. In a cross-sectional
study conducted in the US, 60.1% of patients
who were taking thyroid drugs had normal TSH,
while 18.3% were hypothyroid and 21.6% were
hyperthyroid [80]. There was therefore no sci-
entific explanation for the scale of the surge in
adverse events in France after the reformula-
tion, which may have been largely fueled by
poor communication (many patients were not
initially informed about the change or the need
to check TSH levels if they noticed any change
in their overall health), social media and the
nocebo effect [21, 43].
Similar problems occurred in New Zealand
and Denmark a decade ago in relation to refor-
mulated Eltroxin [21, 43, 74, 81]. A major
review of the New Zealand situation also found
no clear reason for the level of reported adverse
events with reformulated Eltroxin [82]. Again,
suggested contributing factors included poor
communication and intense media interest
[74, 81, 82]. Misinterpretation of the new
formulation, which looked different to the old
formulation may also have been a factor, i.e., a
belief that the new formulation was generic
leading to negative perceptions (nocebo effect)
[82]. Alternative brands were made available in
both countries, and the level of adverse event
reporting returned to baseline, with many
patients still receiving the new Eltroxin formu-
lation [21, 74].
CONCLUSIONS
Physicians should alert patients that their LT4
prescription may be switched at the pharmacy,
encourage patients to ask to remain on the same
preparation at every refill, and make sure that
patients understand that they need to have
their TSH retested every time their LT4 product
is switched [13, 19]. In some countries, such as
the USA and Denmark, physicians can state on
the prescription that switching is not allowed
[2].
Great care must be taken to keep clinicians
and patients fully informed when a reformu-
lated branded product is introduced, and phar-
macovigilance plans should be in place to
monitor adverse events [21, 24, 81].
Patients need to understand that the rec-
ommendation to stay on the same LT4 formu-
lation is based on the concern that switching
products could lead to changes in TSH that
require TSH testing and dose adjustment [3].
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